September 2008 Volume 4, Issue 9
Volume 4, Issue 9 | September 2008
September 2008
In this Issue
Research & Development
Changing the R&D landscape
Lilly sells Greenfield Labs, signs 10-year, $1.6 billion R&D deal with CovanceVenturing into vaccines
Sanofi Pasteur to buy vaccine supplier AcambisClear kidney connection
Cytochroma, Mitsubishi Tanabe ink deal for chronic kidney disease therapeuticsWhat’s old is new again
PhytoMedical to develop Dartmouth’s forgotten cancer compoundsMaking their mark
Biomarker company Clinical Data acquires Adenosine TherapeuticsGlobal News
ImClone says no to BMS
Oncology biopharma rejects BMS' $4.5B acquisition offerAlpharma: ‘No thanks’ to $1.4 billion offer
King Pharmaceuticals makes unsolicited $33 per share bid for specialty pharma companyBack in the game
PDL BioPharma inks deal with Bristol-Myers Squibb for multiple myeloma candidate elotuzumabValeant, Meda strike multiple deals
Valeant sells Western, Eastern Europe operations to Meda for $392 millionMediGene sells European Oracea rights to Galderma
Milestone payments to total up to E32 millionGenomics & Proteomics
Of mice and HIV models
Researchers come up with a more humanized HIV mouse modelFocus on the gene scene
Broad Institute releases free Integrative Genomics Viewer‘Zoom lens’ for sequencing
TGen and febit collaborate to refine new DNA capture methodFollow the leader
Alnylam arranges licenses to gain dominant IP position in RNAaRosetta, NIH to ID microRNA drug targets
In a collaboration that aims to find potential drug targets for treating human immunodeficiency virus (HIV) infection, Rosetta Genomics—which has headquarters both in Israel and Jersey City, N.J.—will work with the National Institutes of Health (NIH) to identify microRNAs implicated in HIV viral replication and their function.Informatics
The power of Pattern Array
University of Maryland researchers see commercial opportunity for novel data mining softwareBreaking down clinical barriers
Pharsight, CRI Worldwide team up to improve clinical trial efficiencyA sum greater than its parts
SDI combines forces with Verispan to create comprehensive healthcare industry databaseClinic-to-research connection
Sealy Center, GenoLogics to develop biomedical informatics solutionA broader protein vision
Waters teams with Proteome Software for protein visualizationEditor's Focus
Few bargains in biotech acquisitions
A funny thing happened on the way to the biotech bargain basement the big companies had been picking over, the pharmas and biotechs on display like so many shirts on a clearance rack at Nordstrom’s: the acquisition targets started saying, “No, we don’t want your funny billion dollars, we’re worth more.”Commentary
At what cost (overzealous) reactions?
Franklin Roosevelt suggested that “the only thing we have to fear is fear itself.” There are many other things to fear, and one of them is poorly reported medical data.Pharma faces Congressional battles in 2009
Industry sees little difference in proposed policies of Obama and McCainAutomation & Instrumentation
Multi-mode partnership
BioTek and fledgling assay company Gyrasol sign co-marketing agreementCustom-made deal
Invitrogen, Lentigen to provide custom lentiviral gene-overexpression productsFluorescent tags for live cells
Promega, Leica set sights on sub 100 nm live cell imagingCaliper extends screening services
Adds RapidKinase profiling and enzymatic mechanism of action studiesFeature
